ZVRA Stock Forecast & Price Target

Zevra Therapeutics Inc demonstrates a positive financial outlook driven by the strong launch of its product MIPLYFFA for Niemann-Pick type C (NPC), with reported sales of $10.1 million in Q4 2024, significantly surpassing initial estimates. The company has shown promising growth, as evidenced by an increase in TRx enrollment forms from 90 to 109 in just two months, indicating strong patient demand and successful outreach strategies. Additionally, the continued expansion of patient awareness and a potential EU filing in 2H25 further enhances the revenue generation prospects as Zevra aims to address unfulfilled treatment needs in the rare disease community.

Zevra Therapeutics Inc. reported a GAAP net income loss of $20.4 million, exacerbated by significant non-cash expenses, including a $15.4 million tax accounting charge and $2.7 million in adjustments related to warrants and derivatives. The company faces multiple challenges that could hinder its revenue growth, such as poor payer coverage affecting market entry for its drugs, increased competition impacting demand for Miplyffa, and emerging safety concerns that may lead to higher discontinuation rates. Additionally, Zevra's ongoing losses, as evidenced by a fourth-quarter net loss of $35.7 million and the slow launch of its product Olpruva, raise concerns about the company's path to achieving profitability and long-term viability in the market.